Outcomes of icotinib combined with concurrent chemoradiotherapy in locally advanced cervical cancer

Abstract

Concurrent chemoradiotherapy (CRT) based on cisplatin is recognized as the current standard treatment for locally advanced cervical cancer. The treatment of cervical cancer has reached a plateau in the last 20 years. Previous studies have proven that the epidermal growth factor receptor is correlated with chemo-and radioresistance and treatment failure. Hence, the purpose of this study was to investigate the efficacy and safety of icotinib combined with CRT in the treatment of locally advanced cervical cancer.Eligibility criteria included patients treated in the radiotherapy department of Taizhou Central Hospital of Zhejiang Province for stage IIB to IIIB cervical cancers who had not received anti-tumor treatment before and a performance status of 0 to 2. Patients were given icotinib 125 mg three times a day for 6 weeks, which was one week before the start of radiotherapy (500 centigrays in 28 fractions) and chemotherapy (40 mg/m 2 administered weekly for 3-5 cycles).There were 29 patients who completed the I + CRT treatment, and it was tolerated well. The median follow-up time was 50 months and 27 patients (93.10%) achieved complete responses. The 5-year cumulative overall survival rate and disease-free survival rate were 60.9% and 58.4%, respectively.The treatment with I + CRT is safe and effective for locally advanced cervical cancer. As far as we know, this is the first study to report the 5-year survival rate of locally advanced cervical cancer with targeted therapy combined with chemoradiotherapy.

Development and internal validation of a nomogram for predicting survival of nonoperative EGFR-positive locally advanced elderly esophageal cancers

“…Icotinib, an oral EGFR-TKI, modulates cell survival and proliferation by inhibiting the phosphorylation of tyrosine kinase in downstream signaling proteins, obstructing the activation of (15,(36)(37)(38)(39)(40). Both the EVIDENCE (38) and CONVINCE (41) studies demonstrated that icotinib considerably reduced DFS and serious adverse effects compared to chemotherapy for patients with EGFR-mutated lung adenocarcinoma.…”

“…Zhang et al (42) found that icotinib enhanced the radiation sensitivity of lung cancer cells by inhibiting the activation of MAPK/ERK/AKT pathway. Zhao et al (37) indicated that icotinib, combined with concurrent radiotherapy, was safe and effective in the treatment of locally advanced squamous cervical cancer. Wang et al (28) reported the favorable efficacy and safety of icotinib as a standalone treatment for EGFR-mutated esophageal cancer, suggesting that icotinib could be a viable treatment for elderly patients (43).…”

eTranscriptional factor CCAAT enhancer binding protein beta inhibits epithelial-mesenchymal transition in cervical cancer via regulating attractin-like 1

“…At present, operation, chemotherapy and radiotherapy are the most commonly used treatments for CC (5). The 5-year survival rate of patients with advanced CC is not high, only approximately 50% (6). In recent years, the incidence of CC has a rising and younger trend (7,8).…”